Mission Statement, Vision, & Core Values of Twist Bioscience Corporation (TWST)

You're looking past the financials to understand the engine of a company like Twist Bioscience Corporation, and that's smart; their Mission, Vision, and Core Values are the non-financial scaffolding holding up the growth story. Honestly, how a company with a $77.7 million net loss in fiscal year 2025-a significant improvement from the prior year, to be fair-can still drive $376.6 million in record revenue and ship nearly 938,000 genes comes down to the clarity of its purpose. Do you know what principles are driving their push toward adjusted EBITDA breakeven, and more importantly, are those principles robust enough to sustain their unique silicon-based DNA Synthesis Platform (a process that writes DNA on a chip, not a plastic plate) advantage?

We need to look at what they value, what they aim to be, and what they actually do to gauge the defintely real-world risk and opportunity ahead. Let's see if their guiding principles-Grit, Impact, Service, and Trust-are truly embedded in the business model that saw their gross margin jump to 50.7% in 2025. What does the company's stated ambition to improve health and sustainability mean for your investment thesis?

Twist Bioscience Corporation (TWST) Overview

You're looking for the core story behind Twist Bioscience Corporation, and it boils down to one thing: they are fundamentally changing how DNA is made. This isn't just incremental improvement; it's a radical shift using a proprietary silicon-based DNA Synthesis Platform that delivers precision and scale that traditional methods just can't match.

Founded in 2013, Twist Bioscience set out to industrialize synthetic biology (SynBio), which is essentially the engineering of biological parts and systems. Their core innovation is miniaturizing the chemical process for DNA synthesis onto a silicon chip, like a semiconductor chip for biology. This allows them to produce high-quality synthetic DNA, RNA, and proteins for customers in medicine, agriculture, and industrial chemicals.

For the full fiscal year 2025, the company's total revenue hit a record $376.6 million, a solid 20% jump from the previous year. This growth shows that their platform is resonating with a diverse customer base, from academic researchers to major biopharmaceutical companies. If you want to dive deeper into how this platform works and the company's full history, you can check out Twist Bioscience Corporation (TWST): History, Ownership, Mission, How It Works & Makes Money.

Fiscal Year 2025 Financial Performance: Record Revenue and Margin Strength

The latest financial reports for the fiscal year ended September 30, 2025, show a business accelerating its operational efficiency while driving top-line growth. Total revenue reached $376.6 million, an increase of 20% year-over-year, which is a defintely strong signal in the biotech space.

The growth wasn't just a single-product story, but a broad-based expansion across all segments. The Next-Generation Sequencing (NGS) segment was the biggest revenue driver, bringing in $208.1 million and growing 23% in fiscal 2025. This is where they sell the tools to prepare DNA for sequencing. The Synthetic Biology (SynBio) segment, which includes synthetic genes, grew 17% to $145.0 million.

Here's the quick math on their main revenue streams for FY 2025:

• NGS Revenue: $208.1 million (55% of total revenue)
• SynBio Revenue: $145.0 million (38% of total revenue)
• Biopharma Revenue: $23.5 million (7% of total revenue)

Plus, they shipped approximately 938,000 genes in fiscal 2025, marking a 22% increase in unit volume. The company also significantly improved its gross margin for the year to 50.7%, up from 42.6% in fiscal 2024, showing that their cost-engineering efforts are paying off.

Positioning as an Industry Leader in Synthetic DNA

Twist Bioscience is not just a participant; they are a leader in the synthetic DNA and sequencing technology space. Their proprietary platform gives them a clear advantage in cost, speed, and the sheer scale of DNA production, which is a major differentiator in a competitive market.

The market opportunity is massive, especially in Next-Generation Sequencing. The total addressable market for NGS is estimated to be around $3 billion, and Twist Bioscience currently holds less than 10% of that market. This means the runway for growth is substantial.

Their technology is also a key enabler for the booming field of AI-driven drug discovery, with orders from AI companies increasing by more than $25 million year-over-year in fiscal 2025. They are translating their platform leadership into tangible commercial success, which is why analysts are watching them closely. The company's focus on new offerings, like the upcoming MRD Express cancer monitoring product, aims to solidify their position in high-value, personalized diagnostics.

Twist Bioscience Corporation (TWST) Mission Statement

If you're looking at a growth-stage biotech like Twist Bioscience Corporation, the mission statement isn't just marketing fluff; it's the strategic roadmap that dictates where every research dollar, every sales effort, and every capital expenditure goes. The core mission is clear: To improve health and sustainability through synthetic DNA. This statement grounds their entire operation, from the lab bench to the P&L statement, by focusing on two massive, long-term global markets.

This mission is what allows them to command a gross margin of 50.7% in fiscal year 2025, up significantly from 42.6% the year before. That jump didn't happen by accident. It's the direct result of their technology platform delivering on the promise of the mission-precision at scale. It's a defintely solid foundation for a company that saw total revenue hit $376.6 million for the full fiscal year 2025.

Core Component 1: Improving Health and Sustainability

The first pillar of the mission is about impact, not just revenue. Twist Bioscience Corporation explicitly ties its success to solving major global problems in two areas: health and environmental sustainability. This isn't abstract, but concrete, especially when you look at their technology's efficiency.

• Focus on therapeutics and diagnostics.
• Enable bio-based chemicals and agriculture.
• Reduce environmental footprint of DNA synthesis.

For instance, their silicon-based DNA synthesis platform dramatically improves sustainability by enabling an estimated 90% reduction in raw material consumption compared to traditional methods. You can see this commitment in their Biopharma segment, which is focused on drug discovery, and which grew its revenue by 15% to $23.5 million in fiscal year 2025. They are enabling the next generation of therapeutics, and doing it with a smaller environmental footprint. It's a win-win for investors who care about both returns and ESG (Environmental, Social, and Governance) factors.

Core Component 2: Manufacturing Synthetic DNA Using a Silicon-Based Platform

The second component is the 'how'-the proprietary technology that makes the mission possible. Twist Bioscience Corporation's competitive moat is its unique semiconductor-based DNA synthesis platform. This technology miniaturizes the chemical process, allowing for high-throughput (HTP) production at a lower cost and with higher quality than competitors.

Here's the quick math on scale: In fiscal year 2025, the company shipped approximately 938,000 genes, which was a 22% increase from the prior year. This massive scale is what drives the financial leverage. It allows them to reduce their net loss to $(77.7) million in FY2025, a huge improvement from the $(208.7) million loss in FY2024, by spreading fixed costs over a much larger volume of product. This platform is the engine. If you want to dive deeper into the market dynamics of this technology, you should check out Exploring Twist Bioscience Corporation (TWST) Investor Profile: Who's Buying and Why?

Core Component 3: Providing Tools to Accelerate Science and Enable Customers

The final core component is the 'who' and 'what for'-the focus on serving the researcher and accelerating their work. The company views itself as an enabler, providing the foundational tools for fields like drug discovery, diagnostics, and data storage. They know that the faster their customers can innovate, the more DNA they will need.

This commitment is evident in their customer base and product speed. They shipped products to roughly 2,484 customers in the third quarter of fiscal 2025 alone. To meet the demand for speed in next-generation sequencing (NGS) and synthetic biology (SynBio), they launched products like Express Genes, which promise perfect-quality clonal genes with a turnaround time of just 5 business days. That speed is a game-changer for researchers. The NGS segment, which is a key tool for diagnostics, grew its revenue by 23% to $208.1 million in fiscal year 2025, showing that customer demand for these high-speed, high-quality tools is robust and growing. They are optimizing for their customer's time, and the market is rewarding that focus.

Twist Bioscience Corporation (TWST) Vision Statement

You're looking for the anchor points of Twist Bioscience Corporation's strategy, and honestly, it all boils down to their core vision: making DNA synthesis so cheap, fast, and precise that it changes everything. The company isn't just selling synthetic DNA; they are selling a manufacturing revolution. Their fiscal year 2025 results defintely show this vision is translating into real numbers, with total revenue hitting a record $376.6 million, a 20% jump year-over-year.

Here's the quick math: that revenue growth, coupled with a gross margin increase to 50.7%, tells me their silicon-based platform (the engine of their vision) is driving efficiency, which is the whole point of a disruptive technology.

Provide a Disruptive Synthetic DNA Manufacturing Platform

The first part of the vision is about technology, specifically their silicon-based DNA Synthesis Platform. This isn't a minor tweak; it's a fundamental shift, moving DNA production from a slow, batch process to a high-throughput, semiconductor-style operation. This platform is the core competitive advantage, enabling precision at a scale competitors simply can't match.

In fiscal year 2025, this platform's output was staggering: they shipped approximately 938,000 genes, which is a 22% increase from the prior year. That massive volume is what drives down the cost per gene, making synthetic biology accessible to more researchers and industries. It's what allows them to focus on SynBio (synthetic biology) revenue, which grew to $145.0 million for the year. The platform is the foundation; without it, the rest of the vision crumbles.

Enable Customers to Address Significant Global Challenges

A vision must look outward, and Twist Bioscience Corporation maps its technology directly to solving big, global problems. The company's products-synthetic genes, oligo pools, and Next-Generation Sequencing (NGS) tools-are the building blocks for solutions in medicine, agriculture, and industrial chemicals.

You see this impact across their segments: NGS tools revenue, which is critical for diagnostics and cancer research, was the largest segment at $208.1 million in FY2025. Plus, their Biopharma revenue, which includes antibody discovery services, grew to $23.5 million. This growth isn't just sales; it's the acceleration of drug discovery, a direct line to improving health. The demand from AI-driven drug discovery companies, for instance, drove over $25 million in order growth from 2024 to 2025, showing where the real-world application of their synthetic DNA is taking off.

Become the Leading Provider of Synthetic Biology Tools and Solutions

The final component is the ambition to lead the market. This isn't just about being big; it's about being the indispensable partner for synthetic biology (SynBio). Leadership requires both scale and financial discipline, and the company is making strides on the latter, significantly narrowing its Net Loss to $(77.7) million for FY2025, compared to a loss of $(208.7) million the year before. That's a huge improvement.

What this estimate hides, however, is the continued focus on profitability, with management targeting adjusted EBITDA break-even by the end of fiscal 2026. For now, the company maintains a strong cash position of $232.4 million to fund this growth and market leadership push. Leadership means providing the full suite of tools, from synthetic genes to antibody discovery, and their revenue breakdown shows a balanced, growing portfolio. If you want a deeper dive into the numbers, you should read Breaking Down Twist Bioscience Corporation (TWST) Financial Health: Key Insights for Investors.

Mission: Improve Health and Sustainability

The mission is the one-sentence purpose that guides the vision: To improve health and sustainability through synthetic DNA. This is plain English and honest. It grounds their high-tech platform in a human outcome. They are using their platform to provide the tools for researchers to advance fields like drug discovery, diagnostics, and even data storage.

The mission directly informs their operational choices, such as the silicon platform reducing raw material consumption-a clear nod to sustainability. Everything they do must tie back to these two pillars: health and sustainability. If a project doesn't serve one of those, it's likely a distraction they should cut.

Core Values: Grit, Impact, Service, Trust

A company's Core Values are the behavioral guardrails, the non-negotiable principles for how they execute the mission and vision. Twist Bioscience Corporation's are simple and action-oriented:

• Grit: Show perseverance for long-term goals.
• Impact: Focus on making a meaningful difference.
• Service: Prioritize customer needs and support.
• Trust: Build relationships based on integrity.

You can see the 'Grit' in the multi-year effort to scale their platform and drive down their Net Loss Per Share from $(3.60)$ in FY2024 to $(1.30) in FY2025. That improvement doesn't happen without a lot of perseverance. 'Service' is reflected in the fact they shipped to approximately 2,484 customers in the third quarter of FY2025 alone, showing a broad and deep customer base they are supporting. These values are the cultural foundation that supports the technical and financial goals.

Twist Bioscience Corporation (TWST) Core Values

You want to understand what truly drives a company like Twist Bioscience Corporation, especially when their financial trajectory is showing real momentum. The company's core values aren't just posters on a wall; they're the operating principles that explain how they grew revenue to $376.6 million in fiscal year 2025, a 20% jump year-over-year. That kind of growth doesn't happen by accident.

For a deep dive into the numbers that underpin this strategy, you should check out Breaking Down Twist Bioscience Corporation (TWST) Financial Health: Key Insights for Investors. But for now, let's map their values-Grit, Impact, Service, and Trust-to the concrete actions that are shaping their market position in late 2025.

Grit

Grit, for Twist Bioscience Corporation, means demonstrating the perseverance and passion needed to achieve long-term goals in a tough, competitive industry. This isn't about short-term wins; it's about the relentless pursuit of a disruptive technology (synthetic DNA) that requires significant upfront investment and R&D. Here's the quick math: the company improved its Gross Margin to 50.7% in fiscal 2025 from 42.6% the year prior. That 8.1 percentage point gain is a direct result of continuous process improvement initiatives and cost savings, which takes real grit.

They're not profitable yet, with a Net Loss of $(77.7) million in FY2025, but that's a massive improvement from the prior year's loss, showing they are defintely moving in the right direction. They are focused on the long game.

• Improve margins through process discipline.
• Scale production despite complex technology.

Impact

Impact means focusing on making a meaningful difference for customers and the world, aligning their synthetic DNA platform with their mission to improve health and sustainability. You see this in their product strategy, which prioritizes high-growth, high-value applications. For instance, Next-Generation Sequencing (NGS) tools are a major segment, and they accounted for 55% of their total revenue in fiscal 2025.

A clear action of this value was the spin-out of the DNA data storage application into Atlas Data Storage. This move allows the core company to accelerate its journey toward profitability by maintaining a sharp focus on its foundational synthetic biology and biopharma operations, maximizing the impact of its resources. They also shipped approximately 938,000 genes in FY2025, a 22% increase, directly enabling more research globally.

Service

The Service value is about prioritizing customer needs and providing exceptional support, which is critical when you're selling complex, custom biological tools. The company's focus on customer experience is measurable: they shipped products to approximately 2,484 customers in the third quarter of fiscal 2025, an increase from 2,300 customers in the same period a year earlier.

Their product portfolio reflects this customer-first mindset. The introduction of Express Genes provides 'perfect-quality clonal genes' with a rapid turnaround time of just five business days. That's a direct response to the market's need for speed, helping researchers move faster. They also expanded the Express portfolio in FY2024 to include Multiplexed Gene Fragments and IgG proteins, scaling their production capabilities to meet diverse customer demands.

Trust

Building Trust is about integrity and reliability, both in their product quality and their commitment to the broader community. In the highly regulated world of synthetic biology, product quality is non-negotiable. Their proprietary silicon-based platform is the foundation of this trust, enabling the cost-effective, precise, and high-throughput synthesis of DNA.

Beyond the product, they build trust through corporate social responsibility. They give every employee eight fully paid hours each year for community volunteering, demonstrating a commitment to giving back and engaging with local organizations. This shows they are invested in the health and sustainability of the world, not just their balance sheet. This commitment to a diverse global workforce and community engagement reinforces their long-term reliability as a partner in the life sciences ecosystem.